ERBB2 and ductal breast carcinoma in situ: Besides, a clinical study used six peptides targeting HER-2 to activate DC1 in vitro and induced a long-lasting Th1 response in 27 patients with DCIS who overexpressed HER-2 (Koski et al., 2012a).